ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc. (ICUI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: ICU Medical develops, manufactures, and sells medical products for infusion therapy, vascular access, and vital care. The company operates as a single reportable segment with three primary product lines: Consumables, Infusion Systems, and Vital Care. In May 2025, the company completed the formation of a joint venture with Otsuka Pharmaceutical Factory America, Inc. (OPF), selling a 60% controlling interest in its IV Solutions business while retaining a 40% stake.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 6.3% to $2.23 billion, primarily driven by a 36.6% drop in Vital Care revenue ($252.8 million decrease) due to the divestiture of the IV Solutions business in May 2025. This was partially offset by growth in Consumables (up 6.8%) and Infusion Systems (up 4.9%).
• Profitability Improvement: Despite lower revenue, the company returned to net income ($0.7 million) from a significant net loss in 2024. This turnaround was driven by a $44.8 million gain on the sale of the IV Solutions business and improved gross margins (36.8% vs. 34.6% in 2024) resulting from the exit of the lower-margin IV Solutions segment.
• Debt Reduction: The company utilized $200 million of proceeds from the IV Solutions sale to prepay Term Loan A. In October 2025, the company refinanced its credit facilities, establishing a new $750 million Term Loan A and $500 million Revolving Credit Facility, reducing overall borrowing costs.
• Tariff Impact: The company incurred $33.6 million in incremental reciprocal tariffs in 2025, with $25.7 million expensed, impacting operating results.

Guidance, Outlook, Risks, and Contingencies

• Capital Expenditures: Management estimates 2026 capital expenditures will range from $85 million to $100 million, focused on manufacturing expansion in Costa Rica, Europe, Mexico, and the U.S.
• Regulatory Risks (FDA): In April 2025, the FDA issued a warning letter regarding modifications to the MedFusion Model 4000 and CADD Solis VIP pumps. The company has filed new 510(k) applications for next-generation devices in July 2025. Resolution is ongoing, and failure to resolve could impact commercial activity.
• Trade and Tariffs: Significant exposure to U.S. trade policy changes. A 15% reciprocal tariff was announced for Costa Rica in July 2025. A Section 232 national security investigation into medical consumables imports was initiated in September 2025, which could lead to additional tariffs.
• Joint Venture: The company retains a 40% interest in the IV Solutions joint venture. While it provides service fees, the company does not have sole decision-making authority, creating potential for impasses or conflicting interests with the majority partner, OPF.
• Effective Tax Rate: The 2025 effective tax rate was 56%, significantly higher than the statutory rate, due to valuation allowances on U.S. deferred tax assets and the mix of U.S. and foreign income.

Investor Verification Checklist

• FDA Warning Letter Resolution: Verify the status of the 510(k) applications for MedFusion and CADD Solis pumps and any potential impact on sales or recalls.
• Tariff Exposure: Assess the financial impact of the 15% tariff on Costa Rican imports and the outcome of the Section 232 investigation on medical devices.
• Joint Venture Performance: Monitor the financial performance of the Otsuka ICU Medical LLC joint venture and the realization of service fee revenues.
• Debt Covenants: Confirm continued compliance with the Senior Secured Leverage Ratio (max 4.00x) and Interest Coverage Ratio (min 3.00x) under the amended credit agreement.
• Valuation Allowance: Review the sustainability of the valuation allowance on U.S. deferred tax assets given the company's recent cumulative losses.